Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy
暂无分享,去创建一个
[1] D. Adams,et al. Familial amyloid polyneuropathy , 2017, Current opinion in neurology.
[2] L. Amass,et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[3] M. Russo,et al. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area , 2016, Journal of Neurology.
[4] H. Morita,et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study , 2016, Journal of the Neurological Sciences.
[5] V. Algalarrondo,et al. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies , 2016, Expert opinion on pharmacotherapy.
[6] R. Labaudinière,et al. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis , 2016, Neurology and Therapy.
[7] O. Suhr,et al. Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry , 2016, Transplantation.
[8] P. Hawkins,et al. Evolving landscape in the management of transthyretin amyloidosis , 2015, Annals of medicine.
[9] T. Coelho,et al. Familial Amyloid Polyneuropathy treatment with Tafamidis – evaluation of one- and two-year treatment in Porto, Portugal , 2015, Orphanet Journal of Rare Diseases.
[10] M. Stewart,et al. Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy , 2015, Orphanet Journal of Rare Diseases.
[11] N. Heaton,et al. Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? , 2015, Transplantation.
[12] R. Falk,et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. , 2015, Circulation. Heart failure.
[13] O. Karayal,et al. Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis , 2014, Neurology and Therapy.
[14] L. Scott. Tafamidis: A Review of Its Use in Familial Amyloid Polyneuropathy , 2014, Drugs.
[15] Y. Sekijima. Recent progress in the understanding and treatment of transthyretin amyloidosis , 2014, Journal of clinical pharmacy and therapeutics.
[16] V. Algalarrondo,et al. FAP Neuropathy and Emerging Treatments , 2014, Current Neurology and Neuroscience Reports.
[17] T. Tripp,et al. Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis , 2013, Journal of Cardiovascular Translational Research.
[18] Teresa Coelho,et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy , 2013, Journal of Neurology.
[19] I. Merkies. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial , 2013, Neurology.
[20] Yukio Ando,et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians , 2013, Orphanet Journal of Rare Diseases.
[21] R. Labaudinière,et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.
[22] M. Saadeh,et al. Liver , 2016, Laboratory Investigation.